THE WHAT? Pfizer announced it will acquire Metsera in a transaction valued at up to US$7.3 billion, including contingent payments, as it seeks to expand its presence in the rapidly growing obesity treatment market.

THE DETAILS Pfizer will pay US$47.50 per share in cash, a 43% premium to Metsera’s last close, with potential milestone payments adding US$22.50 per share. The deal, expected to close in Q4 2025, follows Pfizer’s halted efforts to develop its own obesity pill, danuglipron.

Metsera’s pipeline includes MET-097i, a GLP-1 injectable, and MET-233i, an amylin analogue being tested both as a monthly monotherapy and in combination therapy. Early-stage results for MET-233i indicate a potential “best-in-class” profile, with a monthly dosing schedule viewed by analysts as an advantage for compliance and market differentiation. Leerink Partners estimates more than US$5 billion in peak sales for Metsera’s candidates.

The global obesity drug market is projected to exceed US$150 billion by the early 2030s, currently dominated by Novo Nordisk and Eli Lilly.

THE WHY? The acquisition underscores Pfizer’s need to re-establish momentum in the weight-loss category, after setbacks in its own development programs, and highlights industry competition to secure next-generation GLP-1 and related therapies.

Source: Pfizer